2,413 reports of this reaction
9.6% of all GLYCERIN, LIDOCAINE reports
#2 most reported adverse reaction
ORAL HERPES is the #2 most commonly reported adverse reaction for GLYCERIN, LIDOCAINE, manufactured by Haleon US Holdings LLC. There are 2,413 FDA adverse event reports linking GLYCERIN, LIDOCAINE to ORAL HERPES. This represents approximately 9.6% of all 25,225 adverse event reports for this drug.
Patients taking GLYCERIN, LIDOCAINE who experience oral herpes should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ORAL HERPES is moderately reported among GLYCERIN, LIDOCAINE users, representing a notable but not dominant share of adverse events.
In addition to oral herpes, the following adverse reactions have been reported for GLYCERIN, LIDOCAINE:
The following drugs have also been linked to oral herpes in FDA adverse event reports:
ORAL HERPES has been reported as an adverse event in 2,413 FDA reports for GLYCERIN, LIDOCAINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ORAL HERPES accounts for approximately 9.6% of all adverse event reports for GLYCERIN, LIDOCAINE, making it one of the most commonly reported side effect.
If you experience oral herpes while taking GLYCERIN, LIDOCAINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.